Publications for Catherine B. Small catherine_small@nymc.edu

NYMC School of Medicine
  • Wohl, D. A., Bhatti, L., Small, C. B., Edelstein, H., Zhao, H. H., Margolis, D. A., . . . Shaefer, M. S. (2016). The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Medicine, 17(2), 106-117. doi:10.1111/hiv.12281

  • Rockstroh, J. K., Soriano, V., Plonski, F., Bansal, M., Fatkenheuer, G., Small, C. B., . . .Pineda, J. A. (2015). Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: A randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. HIV Clinical Trials, 16(2), 72-80. doi:10.1179/1528433614Z.0000000011

  • Wohl, D. A., Bhatti, L., Small, C. B., Edelstein, H., Zhao, H. H., Margolis, D. A., . . . Shaefer, M. S. (2014). Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One, 9(5), e96187. doi:10.1371/journal.pone.0096187

  • Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., . . . Small, C. B. (2013). Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet, 382(9893), 700-708. doi:10.1016/S0140-6736(13)61221-0

  • Chur, V., Small, C. B., Stryszak, P., & Teper, A. (2013). Safety of mometasone furoate nasal spray in the treatment of nasal polyps in children. Pediatric Allergy & Immunology, 24(1), 33-38. doi:10.1111/pai.12032

  • Kumar, P., DeJesus, E., Huhn, G., Sloan, L., Small, C. B., Edelstein, H., . . . Felizarta, F. (2013). Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naive, HIV-infected patients (SUPPORT): 96-week results. BMC Infectious Diseases, 13(1), 269. doi:10.1186/1471-2334-13-269